RxDoctor Payments DataLook up a doctor →

Richard Wilkes, MD

Family Medicine · Mt Pleasant, SCNPI 1477847051

Payments from drug & device makers

$215,872in general payments, 2019–2025

Across 1,358 payments — averaging $158.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$112K
  • AbbVie$47K
  • Amgen$43K
  • Pfizer$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$10,6905%
  • Speaking & faculty fees$164,93776%
  • Travel & lodging$18,5899%
  • Food & beverage$21,33510%
  • Education$3210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk236$111,848
AbbVie(2 entities)261$47,450
Amgen(2 entities)114$42,623
Pfizer107$1,558
AstraZeneca(2 entities)50$1,286
Lilly USA, LLC100$1,212
Axsome Therapeutics, Inc.46$955
Avion Pharmaceuticals1$900
Otsuka America Pharmaceutical, Inc.33$612
Esperion Therapeutics, Inc.32$567
GSK29$476
Takeda Pharmaceuticals U.S.A., Inc.24$470
Boehringer Ingelheim29$459
Corium, LLC19$343
Lundbeck LLC16$341
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$335
Amarin Pharma, Inc.18$312
Astellas Pharma US Inc14$281
Teva Pharmaceuticals USA, Inc.15$230
Novartis13$226
Exact Sciences11$212
Dexcom, Inc.6$209
Biohaven Pharmaceutical Holding Company Ltd.11$208
Biohaven Pharmaceuticals, Inc.12$205
Supernus Pharmaceuticals, Inc.6$196
Antares Pharma, Inc.9$180
Sanofi-aventis U.S. LLC10$179
Paratek Pharmaceuticals, Inc.8$155
Johnson & Johnson9$133
Daiichi Sankyo Inc.6$133
Bayer7$128
Idorsia Pharmaceuticals US Inc7$118
Merck7$99
Jazz Pharmaceuticals Inc.5$91
Shire North American Group Inc6$81
Kowa Pharmaceuticals America, Inc.6$78
Boston Scientific3$63
Gilead3$59
Eisai Inc.4$53
Abbott2$49
Neos Therapeutics, LP3$47
Halozyme Inc2$44
Genentech USA, Inc.3$43
Ultragenyx Pharmaceutical Inc.2$43
Noven Therapeutics, LLC2$41
Endo Pharmaceuticals Inc.3$40
E.r. Squibb & Sons, L.L.C.2$36
Alnylam Pharmaceuticals Inc.2$35
Renalytix AI, Inc.2$34
Harmony Biosciences LLC1$33
Clarus Therapeutics Inc.3$31
Zyla Life Sciences, Inc.2$31
Adlon Therapeutics L.p.2$31
Tolmar, Inc.2$29
Kyowa Kirin, Inc.1$28
Ardelyx, Inc.1$26
Bausch Health US, LLC1$25
Aytu Biopharma, Inc.1$22
Nabriva Therapeutics, PLC1$20
Currax Pharmaceuticals LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,872 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$180,402
Medicare patients
288
Services billed
13,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$159,527
JardianceEmpagliflozin55$68,840
MounjaroTirzepatide64$64,775
EliquisApixaban41$34,589
Repatha SureclickEvolocumab22$23,695
JanuviaSitagliptin Phosphate11$17,480
MyrbetriqMirabegron25$17,107
FarxigaDapagliflozin Propanediol15$16,048
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$15,620
XareltoRivaroxaban17$14,686
BelsomraSuvorexant13$14,090
Tresiba Flextouch U-100Insulin Degludec22$9,915
Fiasp FlextouchInsulin Aspart (Niacinamide)19$8,131
Trijardy XrEmpaglifloz/Linaglip/Metformin14$6,610
VascepaIcosapent Ethyl13$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$111,848$159,527111 claims
Boehringer IngelheimJardiance, Trijardy Xr$459$75,45069 claims
Lilly USA, LLCMounjaro$1,212$64,77564 claims
PfizerEliquis$1,558$34,58941 claims
MerckJanuvia, Belsomra$99$31,56924 claims
Astellas Pharma US IncMyrbetriq$281$17,10725 claims
AstraZenecaFarxiga$1,286$16,04815 claims
GSKTrelegy Ellipta$476$15,62011 claims
Johnson & JohnsonXarelto$133$14,68617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →